Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Corporate & Fiscal
Pharmaceutical Events & Conferences
Terms & Conditions
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
ITALY - MARKET REVIEW
The provision of healthcare in Italy, in common with other western European countries, is advanced, with universal access. Being initially based on the NHS-model of the UK, the Italian health service is also facing similar scenarios, most notably efforts to restrain rising costs.
The size of the population ensures that the Italian pharmaceutical market remains the fourth largest in Europe despite the market having the lowest growth rate of all the developed economies. Whilst the overall population is declining, the ratio of those over 65 years of age has already reached 20.3% and is set to rise still further with a corresponding increase in chronic and long term medical conditions. This will inevitably increase demand for pharmaceutical products, placing additional financial strain on the working population to support those of pensionable age. However, cost containment measures are restricting growth in the pharmaceutical market, particularly the retail pharmacy market.
The self-medication market continues to stagnate despite the liberalisation of the pharmacy sector, which has enabled non-prescription medicines to be sold outside pharmacies since August 2006. In 2008, the combined sales of non-prescription drugs that cannot be advertised (SOP – Senza Obligo di Prescrizione Medica) and over-the-counter medicines (OTC) which can be advertised contracted by 3.7%.
Since the introduction of a reference pricing system in 2001, the market share of generic drugs has grown steadily but remains below the European average. The industry association estimated that generics accounted for just 3.1% of pharmaceutical sales by value and 5.9% by volume in 2008, despite double digit increases for several consecutive years. In 2008, sales of unbranded generics increased by 20.2% in value terms and 20.5% in volume. Further expansion is expected following patent expiry on several high volume products in 2007 and 2008.